Initiator Pharma publishes Memorandum and Disclosure Document regarding the Rights Issue
10 juni, 10:45
Initiator Phama A/S ("Initiator" or the "Company") announced on May 19, 2025, that the board had resolved on a rights issue of SEK 56 million (the “Rights Issue”). In connection with the Rights Issue, The Company has prepared a Memorandum and a Disclosure Document.
The Company has published a Disclosure Document that has been prepared in accordance with Article 1.4 (d)(b) of the Prospectus Regulation and prepared in accordance with the requirements set out in Annex IX of the same regulation. Furthermore, the Company has prepared a Memorandum containing detailed guidelines for the Rights Issue.
The Danish Financial Supervisory Authority (In Danish: Finanstilsynet), which is the national competent authority, has neither reviewed or approved the Disclosure Document nor the Memorandum.
Both the Disclosure Document and the Memorandum are available at the Company’s webpage, www.initiatorpharma.com and at Bergs Securities webpage, www.bergssecurities.se.
The record date for the Rights Issue is on June 10, 2025 and the subscription period runs from and including June 12, 2025 up to and including June 26, 2025.
Important information
The publication, disclosure, or distribution of this corporate announcement may be subject to legal restrictions in certain jurisdictions, and persons in the jurisdictions where this press release has been disclosed or distributed should inform themselves of and comply with such legal restrictions. The information in this corporate announcement does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Initiator Pharma. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Denmark and Sweden. The recipient of this corporate announcement is responsible for using this corporate announcement and the information herein in accordance with applicable regulations in the respective jurisdiction. This corporate announcement does not constitute an offer to sell or an invitation regarding an offer to acquire or subscribe for securities issued by the Company in any jurisdiction where such an offer or invitation would be unlawful.
This corporate announcement is not a prospectus in accordance with the definition in the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. In connection with the Rights Issue the Company has prepared a disclosure document in accordance with article 1.4 db of the Prospectus Regulation. The disclosure document has been drafted in accordance with annex IX of the Prospectus Regulation. The Danish Financial Supervisory Authority, which is the competent authority, has not approved nor reviewed the disclosure document. Each investor is advised to make their own assessment of whether it is appropriate to invest in the Company.
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine and IP2018 – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.
Attachments
Initiator Pharma publishes Memorandum and Disclosure Document regarding the Rights Issue
Disclosure Document In Accordance With Annex IX Initiator Pharma FINAL
Memorandum Initiator Pharma FINAL
Ämnen i artikeln
Initiator Pharma publishes Memorandum and Disclosure Document regarding the Rights Issue
10 juni, 10:45
Initiator Phama A/S ("Initiator" or the "Company") announced on May 19, 2025, that the board had resolved on a rights issue of SEK 56 million (the “Rights Issue”). In connection with the Rights Issue, The Company has prepared a Memorandum and a Disclosure Document.
The Company has published a Disclosure Document that has been prepared in accordance with Article 1.4 (d)(b) of the Prospectus Regulation and prepared in accordance with the requirements set out in Annex IX of the same regulation. Furthermore, the Company has prepared a Memorandum containing detailed guidelines for the Rights Issue.
The Danish Financial Supervisory Authority (In Danish: Finanstilsynet), which is the national competent authority, has neither reviewed or approved the Disclosure Document nor the Memorandum.
Both the Disclosure Document and the Memorandum are available at the Company’s webpage, www.initiatorpharma.com and at Bergs Securities webpage, www.bergssecurities.se.
The record date for the Rights Issue is on June 10, 2025 and the subscription period runs from and including June 12, 2025 up to and including June 26, 2025.
Important information
The publication, disclosure, or distribution of this corporate announcement may be subject to legal restrictions in certain jurisdictions, and persons in the jurisdictions where this press release has been disclosed or distributed should inform themselves of and comply with such legal restrictions. The information in this corporate announcement does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Initiator Pharma. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Denmark and Sweden. The recipient of this corporate announcement is responsible for using this corporate announcement and the information herein in accordance with applicable regulations in the respective jurisdiction. This corporate announcement does not constitute an offer to sell or an invitation regarding an offer to acquire or subscribe for securities issued by the Company in any jurisdiction where such an offer or invitation would be unlawful.
This corporate announcement is not a prospectus in accordance with the definition in the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. In connection with the Rights Issue the Company has prepared a disclosure document in accordance with article 1.4 db of the Prospectus Regulation. The disclosure document has been drafted in accordance with annex IX of the Prospectus Regulation. The Danish Financial Supervisory Authority, which is the competent authority, has not approved nor reviewed the disclosure document. Each investor is advised to make their own assessment of whether it is appropriate to invest in the Company.
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com
About Initiator Pharma
Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine and IP2018 – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED. With IP2018 the company has reported positive, statistically significant, and dose-dependent clinical observations related to efficacy in psychogenic erectile dysfunction (ED) in a Phase IIa clinical trial of IP2018 in patients with mild to moderate ED.
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.
Attachments
Initiator Pharma publishes Memorandum and Disclosure Document regarding the Rights Issue
Disclosure Document In Accordance With Annex IX Initiator Pharma FINAL
Memorandum Initiator Pharma FINAL
Ämnen i artikeln
-992x558.png&w=3840&q=75)
Fortnox-budet
-992x558.png&w=3840&q=75)
Investmentbolagen
-160x160.png&w=3840&q=75)
-160x160.jpg&w=3840&q=75)
Storbritannien
Aktieråd
-992x558.jpg&w=3840&q=75)
Fortnox-budet
Investmentbolagen
Storbritannien
Aktieråd
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
-160x160.jpg&w=3840&q=75)